ASCO 2022 | FTD/TPI and bevacizumab versus FTD/TPI monotherapy in metastatic CRC

Trifluridine/tipiracil (FTD/TPI) is currently approved for refractory metastatic colorectal cancer (mCRC). Whilst FTP/TPI plus bevacizumab has shown efficacy and tolerability in Phase I and Phase II trials, few studies have compared FTD/TPI plus bevacizumab versus FTD/TPI alone in mCRC. Takayuki Yoshino, MD, PhD, National Cancer Center Hospital, Chiba, Japan, discusses a meta-analysis conducted to compare FTD/TPI plus bevacizumab with FTD/TPI monotherapy in mCRC. Overall, the meta-analysis indicated the combination to be superior, with a similar safety profile, although associated with a higher rate of grade 3 or more neutropenia. Confirmation of these findings via trials, such as the Phase III SUNLIGHT (NCT04737187) study, are warranted. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.